Wyeth s Ruffolo on Retooling Drug Discovery Operations | GenomeWeb

Wyeth Pharmaceuticals started a process of re-engineering its drug discovery operations five years ago with the goal of improving its performance and identifying more clinical candidates. According to the firm, the process was a major success, and it has the numbers to back up that claim. Dr. Robert Ruffolo, president of research and development for Wyeth Pharmaceuticals, gave a talk last week at the PharmaDiscovery Conference in Washington, DC, describing the organizational changes and ways the firm maximized its use of drug discovery tools to improve productivity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.